New Low-Dose pain patch aims to ease cancer suffering

NCT ID NCT00771199

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a low-dose fentanyl patch in 14 cancer patients in Taiwan to see if it is safe and tolerable for managing pain. The patch delivers pain medicine through the skin over 28 days. The main goal was to see how many patients dropped out due to side effects, with the hope that starting at a lower dose would reduce problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
fentanyl patch
What this could lead to
If successful, this could provide a safer starting dose for managing cancer pain with fewer side effects.
What could go wrong
This is a small, completed Phase 4 study with only 14 participants, so results may not apply broadly. Fentanyl carries risks of addiction and respiratory depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Cancer Pain neoplasm Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Janssen-Cilag Ltd.

    High Wycombe, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.